ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.199G>T (p.Asp67Tyr) (rs80357102)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 18
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000083176 SCV000244311 benign Breast-ovarian cancer, familial 1 2015-08-10 reviewed by expert panel curation IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 0.0000029
Invitae RCV000195312 SCV000075688 benign Hereditary breast and ovarian cancer syndrome 2020-11-20 criteria provided, single submitter clinical testing
CSER _CC_NCGL, University of Washington RCV000148404 SCV000190103 uncertain significance Breast and/or ovarian cancer 2014-06-01 criteria provided, single submitter research Low GERP score may suggest that this variant may belong in a lower pathogenicity class
GeneDx RCV000047675 SCV000209902 likely benign not specified 2017-08-28 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Ambry Genetics RCV000162582 SCV000212998 benign Hereditary cancer-predisposing syndrome 2014-11-18 criteria provided, single submitter clinical testing This alteration is classified as benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Counsyl RCV000083176 SCV000220787 likely benign Breast-ovarian cancer, familial 1 2014-10-13 criteria provided, single submitter literature only
CHEO Genetics Diagnostic Laboratory,Children's Hospital of Eastern Ontario RCV000195312 SCV000324827 uncertain significance Hereditary breast and ovarian cancer syndrome 2015-08-27 criteria provided, single submitter clinical testing
Cancer Genetics and Genomics Laboratory,British Columbia Cancer Agency RCV000047675 SCV000586866 likely benign not specified 2017-04-18 criteria provided, single submitter clinical testing
Department of Pathology and Molecular Medicine,Queen's University RCV000047675 SCV000588027 benign not specified 2017-04-20 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000589035 SCV000698905 benign not provided 2017-07-03 criteria provided, single submitter clinical testing Variant summary: This missense variant involves the alteration of a non-conserved nucleotide and 3/5 in silico tools predict a pathogenic outcome. The variant is present at a low frequency in the control population (0.0076% in ExAC, 0.012% in European (Non-Finnish)), and has been reported in the literature in HBOC patients and families. Most of these publications, however, fail to provide co-segregation and co-occurrence data, and do not test for large deletions/insertions, and therefore do not provide strong evidence for the causality of this variant. In addition, one report, although a poster presentation, is provided by individuals from a reputable laboratory, Myriad, indicating the variant was found to co-occur with 9 pathogenic variants (gene and variants not specified) and was classified as benign. UMD lists variant in 15 individuals with classification of "1-Neutral". One of them carried a pathogenic BRCA2 variant c.1773_1776delTTAT (p.Ile591MetfsX22). Furthermore, several functional studies have been published and showed that the c.199G>T variant had a moderate effect on centrosome duplication (Kais_2012, Towler_2013), chromosomal instability, (Cochran_2015), and resulted in a moderate reduction in E3 ligase activity, but that the mutant protein had similar binding of BRCA1 to BARD1 (Caleca_2014, Ransburgh_2010, Morris_2006, Starita_2015) and wild-type levels of E2 interaction (Morris_2006). There was no difference in homologous recombination (Kais_2012, Ransburgh_2010), double strand break repair by the single-strand annealing pathway (Towler_2013), yeast colony size, spot formation, and yeast localization (Thouvenot_2016) between mutant BRCA1 with this variant and wild-type BRCA1. This variant also had no effect on splicing via patient cDNA and minigene splicing assay (Houdayer_2012, Thery_2011). Additionally, multifactorial probability based models showed a low odds in favor of causality (Lindor_2012, Easton_2007). In addition, multiple reputable databases, UMD, ARUP, and clincial labs classify the variant as "benign/likely benign, at-least 2 of whom have submitted/updated their submissions to ClinVar since the time of the previous classification of this variant in our laboratory." Therefore, taking all evidence into consideration, the variant of interest is classified as benign.
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000589035 SCV000883466 likely benign not provided 2017-08-24 criteria provided, single submitter clinical testing
Color Health, Inc RCV000162582 SCV000902756 likely benign Hereditary cancer-predisposing syndrome 2016-07-28 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000083176 SCV001287533 likely benign Breast-ovarian cancer, familial 1 2018-04-24 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign.
Sharing Clinical Reports Project (SCRP) RCV000083176 SCV000115250 uncertain significance Breast-ovarian cancer, familial 1 2007-03-07 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000083176 SCV000144627 uncertain significance Breast-ovarian cancer, familial 1 2002-05-29 no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001353503 SCV000591248 benign Malignant tumor of breast no assertion criteria provided clinical testing The BRCA1 p.Asp67Tyr variant was identified in 4 of 1760 proband chromosomes from individuals or families with breast or ovarian cancer (Blay 2013, Diez 2003); however, control chromosomes from healthy individuals were not evaluated in these studies. The variant was also identified HGMD, LOVD, the BIC database (8X with unknown clinical importance), and UMD (15X as a neutral variant). In UMD, the variant was found to co-occur with a pathogenic BRCA2 mutation (c.1773_1776delTTAT (p.Ile591MetfsX22)) in one sample, increasing the likelihood that the p.Asp67Tyr variant may not have clinical significance. The variant was listed in dbSNP (ID: rs80357102) “With allele of Uncertain significance”, with a minor allele frequency of 0.0005 (1000 Genomes Project), and in the NHLBI Exome Sequencing Project (Exome Variant Server) in 2 of 8582 European American alleles; however the low number and frequency of this variant in these populations is not substantive enough to determine the prevalence of this variant in the general population. This residue is not conserved in mammals and lower organisms and computational analyses (PolyPhen-2, SIFT, AlignGVGD) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. Several function studies found the variant to have a neutral effect on BRCA1 function, including assays evaluating protein binding, homology directed recombination, and single-strand annealing repair (Atipairin 2011, Bouwman 2013, Caleca 2014, Morris 2006, Ransburgh 2010, Towler 2013). One study found that the variant had an intermediate effect on centrosome amplification; however, the authors suggest that this may be on the high end of the normal range (Kais 2012). In addition, two in silico studies using multifactorial probability based models found this variant to be neutral (Easton 2007, Lindor 2012). Furthermore, Myriad classifies this variant as “Favor polymorphism” (personal communication). In summary, based on the above information, this variant meets our laboratory's criteria to be classified as benign.
Brotman Baty Institute,University of Washington RCV000083176 SCV001241658 not provided Breast-ovarian cancer, familial 1 no assertion provided in vitro
King Laboratory,University of Washington RCV000047675 SCV001251392 benign not specified 2019-09-01 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.